Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026, announced August 13, 2026.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced August 13, 2026
- Full financial details and management commentary contained in Exhibit 99.1
- Results announcement gives investors an update on quarterly operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $33.7M, including $26.2M neffy product revenue versus $12.8M in Q2 2025
- U.S. neffy market share reached 5%, while field-targeted accounts reached 8% versus 4% in Q2 2025
- Q2 net loss $62.3M, or $0.63 per share, with operating expenses of $95.1M
- Cash, equivalents, and short-term investments totaled $143.8M, against $96.7M term loans and $74.9M financing liability
- H2 2026 cash-based SG&A and R&D guidance $100M–$110M, supporting targeted cash-flow breakeven by end-2027; CSU data expected Q1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.